Current Liabilities
Operating Lease Liability - Undiscounted Excess Amount
Neurocrine Biosciences Operating Lease Liability - Undiscounted Excess Amount decreased by 9.4% to $126.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 17.1%, from $152.80M to $126.70M.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ2 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
Changes reflect shifts in the discount rates used for lease accounting or changes in the duration of the lease portfolio.
Detailed definition
This represents the difference between the total undiscounted future lease payments and the present value of those payme...
Peer comparison
Used by analysts to reconcile lease accounting differences between companies with varying discount rate assumptions.
Metric ID:
operating_lease_liability_undiscounted_excessHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.30M | $33.80M | $30.90M | $29.30M | $27.80M | $24.90M | $23.90M | $22.40M | $89.50M | $89.40M | $85.90M | $152.80M | $146.70M | $139.80M | $126.70M |
| QoQ Change | — | -4.2% | -8.6% | -5.2% | -5.1% | -10.4% | -4.0% | -6.3% | +299.6% | -0.1% | -3.9% | +77.9% | -4.0% | -4.7% | -9.4% |
| YoY Change | — | — | — | -17.0% | -17.8% | -19.4% | -18.4% | -19.4% | +259.4% | +274.1% | +283.5% | +70.7% | +64.1% | +62.7% | -17.1% |
Range$22.40M – $152.80M
CAGR+44.1%
Avg YoY Growth+75.5%
Median YoY Growth+22.9%
Current Streak3 quarters decline
Operating Lease Liability - Undiscounted Excess Amount at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease liability - undiscounted excess amount?
- Neurocrine Biosciences (NBIX) reported operating lease liability - undiscounted excess amount of $126.70M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liability - undiscounted excess amount changed year-over-year?
- Neurocrine Biosciences's operating lease liability - undiscounted excess amount decreased by 17.1% year-over-year, from $152.80M to $126.70M.
- What does operating lease liability - undiscounted excess amount mean?
- The difference between the total future lease payments and their current value on the balance sheet.